{
  "trial_id": "NCT03336203",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "outpatient adults with gout and hyperurecemia (SUA level above 8 mg/dL (480 \u00b5mol/L))",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "outpatient adults with CKD 1-4 stages and hyperurecemia (SUA level above 8 mg/dL (480 \u00b5mol/L))",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "forms of associated comorbidities and cardiovascular risk factors, including heart failure",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "III-IV NYHA, stroke, peripheral arterial disease, obesity with BMI above 30 kg/m2",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has a history of asthma and uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg. He also has seasonal allergic rhinitis in the summer.",
  "_meta": {
    "topic_id": "23",
    "trial_id": "NCT03336203",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}